# Clinical Trial of Dimolegin (DD217) in Prevention of Thrombotic Complications in Patients With COVID-19

Study · id `cardio:ct-nct05185804` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05185804](<https://clinicaltrials.gov/study/NCT05185804>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT05185804

Browse, organ or system: Heart; Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 399 participants.

## Technical summary

Registry record NCT05185804. Randomized; no masking; primary purpose treatment. Start 2021-02-08 (actual); primary completion 2021-08-06 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 399 participants (enrolled count; ClinicalTrials.gov record NCT05185804, source copy `cardio:ctgov-nct05185804-2022-01-11`, retrieved 2026-10-31)
- Started: 2021-02-08 (actual) (ClinicalTrials.gov record NCT05185804, source copy `cardio:ctgov-nct05185804-2022-01-11`, retrieved 2026-10-31)
- Primary completion: 2021-08-06 (actual) (ClinicalTrials.gov record NCT05185804, source copy `cardio:ctgov-nct05185804-2022-01-11`, retrieved 2026-10-31)
- Completion: 2021-10-29 (actual) (ClinicalTrials.gov record NCT05185804, source copy `cardio:ctgov-nct05185804-2022-01-11`, retrieved 2026-10-31)
- Countries: Russia (ClinicalTrials.gov record NCT05185804, source copy `cardio:ctgov-nct05185804-2022-01-11`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05185804-2022-01-11`, retrieved 2026-10-31)

## The registry's words

- Brief title: Clinical Trial of Dimolegin (DD217) in Prevention of Thrombotic Complications in Patients With COVID-19
- Condition: COVID-19
- Condition: Venous Thromboembolism
- Intervention (Drug): Dimolegin
- Intervention (Drug): Clexane
- Lead sponsor: PharmaDiall Ltd.
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Deep vein thrombosis (`cardio:deep-vein-thrombosis`)
- Registry condition terms include this condition: Pulmonary embolism (`cardio:pulmonary-embolism`)

## Provenance

Content hash: 0c2d259502a8c8661e3a404555482874f1923f447b657600da31a003f3ef35a3
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
